Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19
A combination comprising of ivermectin, zinc and doxycycline could be the fastest and safest way to end the coronavirus pandemic in Australia within two months.
That is the view of Thomas Borody, a Sydney-based gastroenterologist famous for curing peptic ulcers using a triple antibiotic therapy. He has released the triple therapy protocol for COVID-19 to Australian general practitioners (GPs).
"Why are we just waiting around for a vaccine?"He said: "GPs can legally prescribe the therapy today as an off-label treatment according to Australian Guidelines - a standard practice in medicine. In fact, more than 60% of prescriptions in Australia are off-label. It's not a new concept. It's happening every day to manage diseases and save lives.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze